AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11107575 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with good social conditions
Number of subjects: 90
Study 11107575 — intervention group
Group type: COMPARATOR
Intervention: Control group of healthy men aged 18‐24 years
Number of subjects: 90
Study 7789662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sensorimotor therapy for 10 weeks
Number of subjects: 27
Study 7789662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sensorimotor therapy for 20 weeks
Number of subjects: 27
Study 7789662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sensorimotor therapy (10 and 20 weeks)
Number of subjects: 27
Study 2299096 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antigen avoidance diet (D group)
Number of subjects: 115
Study 2299096 — intervention group
Group type: COMPARATOR
Intervention: No maternal antigen avoidance diet (ND group)
Number of subjects: 115
Study 422356 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 30
Study 31856903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) plus behavioral experiments (BEs)
Number of subjects: 60
Study 31856903 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy (CT) as usual
Number of subjects: 60
Study 28372320 — intervention group
Group type: EXPERIMENTAL
Intervention: First-rib high-velocity low-amplitude manipulation technique
Number of subjects: 53
Study 28372320 — intervention group
Group type: COMPARATOR
Intervention: Sham placebo intervention
Number of subjects: 53
Study 25891115 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation (DHA 300 mg/day, EPA 100 mg/day, ARA 120 mg/day)
Number of subjects: 113
Study 25891115 — intervention group
Group type: COMPARATOR
Intervention: Placebo (purified olive oil)
Number of subjects: 113
Study 25891115 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA supplementation
Number of subjects: 113
Study 25891115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 24069148 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mental health approach (online screening and personalized feedback on impaired work functioning and mental health, followed by tailored self-help EMH interventions)
Number of subjects: 1140
Study 24069148 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1140
Study 24069148 — intervention group
Group type: EXPERIMENTAL
Intervention: E-mental health approach
Number of subjects: 1140
Study 24069148 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1140
Study 21248159 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral challenge with MACP
Number of subjects: 0
Study 21248159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with MACP
Number of subjects: 0
Study 21248159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with MACP (prior MCC)
Number of subjects: 0
Study 21248159 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal challenge with MACP (prior MACP)
Number of subjects: 0
Study 18823744 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal-on-metal hip arthroplasty
Number of subjects: 54
Study 18823744 — intervention group
Group type: COMPARATOR
Intervention: Metal-on-polyethylene hip arthroplasty
Number of subjects: 54
Study 17951229 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus estramustine (D + E)
Number of subjects: 0
Study 17951229 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone plus prednisone (M + P)
Number of subjects: 0
Study 15586629 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Input Function (SIF)
Number of subjects: 10
Study 15586629 — intervention group
Group type: EXPERIMENTAL
Intervention: One-point arterial sampling and SIF
Number of subjects: 10
Study 11874551 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid (2 kcal min(‐1)) - Continuous infusion (CID)
Number of subjects: 8
Study 11874551 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Intralipid (2 kcal min(‐1)) - Pulsatile infusion (PID)
Number of subjects: 8
Study 11874551 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 8
Study 10798029 — intervention group
Group type: EXPERIMENTAL
Intervention: Soap
Number of subjects: 40
Study 10798029 — intervention group
Group type: EXPERIMENTAL
Intervention: Ash
Number of subjects: 40
Study 10798029 — intervention group
Group type: COMPARATOR
Intervention: Control (no handwashing agent mentioned)
Number of subjects: 40
Study 8926741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (25 mg, cocaine HCl)
Number of subjects: 6
Study 8926741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal cocaine (32 mg, cocaine HCl)
Number of subjects: 6
Study 8926741 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked cocaine (42 mg, cocaine base)
Number of subjects: 6
Study 2181975 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyurethane foam dressings (group 1)
Number of subjects: 36
Study 2181975 — intervention group
Group type: COMPARATOR
Intervention: Unna's boot (group 2)
Number of subjects: 36
Study 7009440 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg i.v.)
Number of subjects: 6
Study 7009440 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mcg per inhalationem)
Number of subjects: 6
Study 30335672 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc nanocolloid
Number of subjects: 27
Study 30335672 — intervention group
Group type: COMPARATOR
Intervention: Tc tin colloid
Number of subjects: 27
Study 30558143 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (BCAA, arginine, citrulline)
Number of subjects: 16
Study 30558143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27246705 — intervention group
Group type: EXPERIMENTAL
Intervention: Central bundling (zinc and ORS bundled using a pouch with instructional message)
Number of subjects: 704
Study 27246705 — intervention group
Group type: EXPERIMENTAL
Intervention: HC level bundling (zinc, ORS and a similar pouch distributed to the HCs and bundled by health workers)
Number of subjects: 704
Study 27246705 — intervention group
Group type: COMPARATOR
Intervention: Bundling without message (zinc, ORS and plain pouch distributed and bundled by health workers)
Number of subjects: 704
Study 27246705 — intervention group
Group type: COMPARATOR
Intervention: Status quo (zinc and ORS co-administered without bundling)
Number of subjects: 704
Study 24673668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound localization of the puncture site
Number of subjects: 100
Study 24673668 — intervention group
Group type: COMPARATOR
Intervention: Palpation of spinal landmarks
Number of subjects: 100
Study 22818493 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus financial voucher incentives to engage with cessation services
Number of subjects: 600
Study 22818493 — intervention group
Group type: COMPARATOR
Intervention: Standard care for pregnant smokers
Number of subjects: 600
Study 20879813 — intervention group
Group type: EXPERIMENTAL
Intervention: New surgical method using a postauricular pedicle periosteal flap and free temporal fascia grafts (Group I)
Number of subjects: 25
Study 20879813 — intervention group
Group type: COMPARATOR
Intervention: Standard operation using only free temporal fascia grafts (Group II)
Number of subjects: 25
Study 18300441 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound betamethasone injection (1 ml, postaural, single injection)
Number of subjects: 27
Study 18300441 — intervention group
Group type: COMPARATOR
Intervention: Merislon and Sibelium (peroral for 2 weeks)
Number of subjects: 27
Study 15185808 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 20
Study 15185808 — intervention group
Group type: COMPARATOR
Intervention: No BIS monitoring
Number of subjects: 20
Study 12151964 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin 130 mg/m2 on day 1 and daily oral UFT 350 mg/m2 in 3 divided doses for 21 days, repeated every 21 days
Number of subjects: 34
Study 9669186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 217
Study 9669186 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 217
Study 9669186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 11271190 — intervention group
Group type: EXPERIMENTAL
Intervention: Piggy-back (PB) liver transplantation
Number of subjects: 40
Study 11271190 — intervention group
Group type: COMPARATOR
Intervention: Standard technique liver transplantation
Number of subjects: 40
Study 3290517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg orally twice daily (suppressive treatment)
Number of subjects: 950
Study 3290517 — intervention group
Group type: COMPARATOR
Intervention: Placebo (episodic treatment)
Number of subjects: 950
Study 3290517 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir (suppressive therapy)
Number of subjects: 950
Study 3290517 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (episodic therapy)
Number of subjects: 950
Study 29104118 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel hydrochloride (prasugrel)
Number of subjects: 341
Study 28027810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/3 IPV‐Al
Number of subjects: 240
Study 28027810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/5 IPV‐Al
Number of subjects: 240
Study 28027810 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10 IPV‐Al
Number of subjects: 240
Study 28027810 — intervention group
Group type: COMPARATOR
Intervention: IPV Vaccine SSI
Number of subjects: 240
Study 28027810 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 240
Study 25588907 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity (additional physical activities such as standing or walking)
Number of subjects: 198
Study 25588907 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus (social activities such as card and board games)
Number of subjects: 198
Study 25588907 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced physical activity
Number of subjects: 198
Study 25588907 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus
Number of subjects: 198
Study 24002555 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Q Amplified DNA Assay (CTQ) using SurePath media
Number of subjects: 4002
Study 24002555 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Q Amplified DNA Assay (GCQ) using SurePath media
Number of subjects: 4002
Study 24002555 — intervention group
Group type: EXPERIMENTAL
Intervention: CT Q Amplified DNA Assay (CTQ) using PreservCyt media
Number of subjects: 4002
Study 24002555 — intervention group
Group type: EXPERIMENTAL
Intervention: GC Q Amplified DNA Assay (GCQ) using PreservCyt media
Number of subjects: 4002
Study 21915543 — intervention group
Group type: EXPERIMENTAL
Intervention: Trochanteric portal (Group B)
Number of subjects: 110
Study 21915543 — intervention group
Group type: COMPARATOR
Intervention: Piriformis fossa portal (Group A)
Number of subjects: 110
Study 21915543 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 17554786 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (7 mg/kg administered intraperitoneally on Days 0 and 21)
Number of subjects: 40
Study 16631836 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser pulpotomy
Number of subjects: 137
Study 16631836 — intervention group
Group type: COMPARATOR
Intervention: Formocresol pulpotomy
Number of subjects: 137
Study 15008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise White Sealant with air abrasion or air polishing followed by etching
Number of subjects: 120
Study 15008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Seal with air abrasion or air polishing followed by etching
Number of subjects: 120
Study 15008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid etching (applied to both sealants)
Number of subjects: 120
Study 15008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of air abrasion and phosphoric acid etching
Number of subjects: 120
Study 15008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Concise White Sealant
Number of subjects: 120
Study 15008338 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyract Seal
Number of subjects: 120
Study 10764336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pethidine (analgesia group)
Number of subjects: 50
Study 10764336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (placebo group)
Number of subjects: 50
Study 8962480 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning group with articulatory suppression during both learning and stress trials
Number of subjects: 32
Study 8962480 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning group without articulatory suppression during stress trials
Number of subjects: 32
Study 8962480 — intervention group
Group type: COMPARATOR
Intervention: Explicit learning group
Number of subjects: 32
Study 8354027 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (250 mg intravenously)
Number of subjects: 10
Study 8354027 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg chewing gum)
Number of subjects: 10
Study 8354027 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and nicotine
Number of subjects: 10
Study 8354027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2941966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐dFUrd 5 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Number of subjects: 17
Study 2941966 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐dFUrd 3 g/m2 as a 1‐h infusion for 5 days in 3 cycles at intervals of 4 weeks
Number of subjects: 17
Study 2941966 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (cachectic patients and patients with a pathological EEG before treatment)
Number of subjects: 17
Study 2941966 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG monitoring
Number of subjects: 17
Study 31259807 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocriplasmin (0.125 mg)
Number of subjects: 220
Study 31259807 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 220
Study 29199379 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach (MIS-TKA)
Number of subjects: 50
Study 29199379 — intervention group
Group type: COMPARATOR
Intervention: Medial parapatellar approach (traditional TKA)
Number of subjects: 50
Study 27727279 — intervention group
Group type: EXPERIMENTAL
Intervention: A single ultra-low dose of aldesleukin (0.101 × 106 IU/m2)
Number of subjects: 40
Study 27727279 — intervention group
Group type: EXPERIMENTAL
Intervention: A single ultra-low dose of aldesleukin (0.497 × 106 IU/m2)
Number of subjects: 40
Study 27727279 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest doses of aldesleukin (0.040 × 106 and 0.045 × 106 IU/m2)
Number of subjects: 40
Study 27727279 — intervention group
Group type: EXPERIMENTAL
Intervention: A single ultra-low dose of aldesleukin
Number of subjects: 40
Study 25201345 — intervention group
Group type: EXPERIMENTAL
Intervention: Before school physical activity (PA) intervention, 31 minutes per day, 12 weeks
Number of subjects: 202
Study 25201345 — intervention group
Group type: COMPARATOR
Intervention: Sedentary classroom-based (SC) intervention, 31 minutes per day, 12 weeks
Number of subjects: 202
Study 22877647 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Reactivation and Rehabilitation (IRR) program
Number of subjects: 0
Study 22129171 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole 200 mg slow release twice daily
Number of subjects: 20
Study 22129171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19083719 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric program
Number of subjects: 20
Study 19083719 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 16611307 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCM + P (adriamycin, carmustine (BCNU), cyclophosphamide, melphalan with prednisolone)
Number of subjects: 299
Study 16611307 — intervention group
Group type: COMPARATOR
Intervention: ABCM (adriamycin, carmustine (BCNU), cyclophosphamide, melphalan)
Number of subjects: 299
Study 16611307 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCM + P
Number of subjects: 299
Study 12954577 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 20 mg/day
Number of subjects: 92
Study 12954577 — intervention group
Group type: EXPERIMENTAL
Intervention: Arzoxifene 50 mg/day
Number of subjects: 92
Study 10983645 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV
Number of subjects: 208
Study 10983645 — intervention group
Group type: EXPERIMENTAL
Intervention: RTV/SQV/d4T
Number of subjects: 208
Study 10983645 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF drug concentrations of RTV and SQV
Number of subjects: 208
Study 9187994 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoximone (EN)
Number of subjects: 20
Study 9187994 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine (DOB) and Nitroglycerin (NTG)
Number of subjects: 20
Study 8243699 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic technique (diluted vasopressin 20 U in 20 mL normal saline)
Number of subjects: 21
Study 8243699 — intervention group
Group type: COMPARATOR
Intervention: Mechanical technique (penrose drain tourniquet and vascular clamps)
Number of subjects: 21
Study 8243699 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 21
Study 2871294 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Maintenance Organisation (HMO) for high income initially sick individuals
Number of subjects: 1673
Study 2871294 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Maintenance Organisation (HMO) for low income initially sick individuals
Number of subjects: 1673
Study 2871294 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service (FFS) care for high income initially sick individuals
Number of subjects: 1673
Study 2871294 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-service (FFS) care for low income initially sick individuals
Number of subjects: 1673
Study 31268383 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 418
Study 29426774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 20 mg/kg/day
Number of subjects: 87
Study 29426774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 27416541 — intervention group
Group type: EXPERIMENTAL
Intervention: G5K solution
Number of subjects: 44
Study 27416541 — intervention group
Group type: COMPARATOR
Intervention: Control group (Ringer's maleate solution)
Number of subjects: 44
Study 26054178 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (zinc lactate and magnolia bark extract tablets)
Number of subjects: 100
Study 26054178 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo tablets)
Number of subjects: 100
Study 22521517 — intervention group
Group type: EXPERIMENTAL
Intervention: Meals on Wheels
Number of subjects: 189
Study 22521517 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 189
Study 20404425 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.03%
Number of subjects: 34
Study 20404425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17593869 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 17593869 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 40
Study 16491689 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice with three different visual distortion lenses
Number of subjects: 40
Study 16491689 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice with one of several visual distortion lenses
Number of subjects: 40
Study 16491689 — intervention group
Group type: COMPARATOR
Intervention: Sham lenses
Number of subjects: 40
Study 16491689 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant practice with visual distortion lenses
Number of subjects: 40
Study 12441263 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) for 2 years
Number of subjects: 388
Study 12441263 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years
Number of subjects: 388
Study 12441263 — intervention group
Group type: COMPARATOR
Intervention: Control group (observation only)
Number of subjects: 388
Study 10461302 — intervention group
Group type: EXPERIMENTAL
Intervention: RVS pacing (AAIR)
Number of subjects: 12
Study 10461302 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing (VVIR)
Number of subjects: 12
Study 8603445 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) dose escalation (increased in monthly 25% steps if 75 mg/m2 was tolerated without cytopenias)
Number of subjects: 88
Study 8603445 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (without dose escalation)
Number of subjects: 88
Study 8603445 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalated doses of 6MP (30 children)
Number of subjects: 88
Study 8603445 — intervention group
Group type: COMPARATOR
Intervention: Conventional cohort eligible for escalation (37 children)
Number of subjects: 88
Study 8603445 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MP dose escalation
Number of subjects: 88
Study 1577927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal micronized progesterone (600 mg/day)
Number of subjects: 262
Study 1577927 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular progesterone in oil (50 mg/day)
Number of subjects: 262
Study 6375610 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of phentermine resin (15 mg in the morning) and fenfluramine hydrochloride (30 mg before the evening meal)
Number of subjects: 81
Study 6375610 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine hydrochloride (20 mg three times a day)
Number of subjects: 81
Study 6375610 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine resin (30 mg in the morning)
Number of subjects: 81
Study 6375610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31083846 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reflection (four sessions based on scenarios related to spiritual care)
Number of subjects: 63